MIF aggravates experimental autoimmune prostatitis through activation of the NLRP3 inflammasome via the PI3K/AKT pathway
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112891 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Fei Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, PR China; Institute of Urology, Anhui Medical Univers…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Prostatitis, Macrophage Migration-Inhibitory Factors, Inflammasomes. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Anhui Province, Anhui Medical University.
Abstract (Originalsprache)
In our investigation, we investigated the role of macrophage migration inhibitory factor (MIF), a key cytokine, in chronic nonbacterial prostatitis (CNP), an underexplored pathology. Elevated MIF expression was observed in the serum of individuals with chronic prostatitis-like symptoms (CP-LS) as well as in serum and tissue samples from experimental autoimmune prostatitis (EAP) mouse model. Treatment with ISO-1, a specific MIF antagonist, effectively mitigated prostatic inflammation and macrophage infiltration, thereby emphasizing the critical role of MIF in orchestrating immune responses within the prostate microenvironment. Further analyses revealed that MIF stimulates the PI3K/AKT and NLRP3 inflammasome pathways, which are integral to inflammation and cellular immunity. Pharmacological inhibition of the PI3K/AKT pathway by LY294002 substantially reduced prostatic inflammation and macrophage infiltration, potentially by inhibiting NLRP3 inflammasome activation. These findings collectively suggest that MIF is a potential diagnostic marker for CNP and suggest that targeting MIF or its downstream signalling pathways, PI3K/AKT and NLRP3, might represent a novel therapeutic strategy for this condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, PR China; Institute of Urology, Anhui Medical University, Hefei 230022, PR China; Anhui Province Key Laboratory of Urologic…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province
- Anhui Medical University
Zitieren
APA
Zhang, F., Meng, T., Feng, R., Jin, C., Zhang, S., Meng, J., Zhang, M., & Liang, C. (2024). MIF aggravates experimental autoimmune prostatitis through activation of the NLRP3 inflammasome via the PI3K/AKT pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112891
Vancouver
Zhang F, Meng T, Feng R, Jin C, Zhang S, Meng J, et al. MIF aggravates experimental autoimmune prostatitis through activation of the NLRP3 inflammasome via the PI3K/AKT pathway. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112891
BibTeX
@article{Zhang2024,
author = {Zhang, Fei and Meng, Tong and Feng, Rui and Jin, Chen and Zhang, Song and Meng, Jialin and Zhang, Meng and Liang, Chaozhao},
title = {MIF aggravates experimental autoimmune prostatitis through activation of the NLRP3 inflammasome via the PI3K/AKT pathway},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112891}
}
EUVIMED